TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lineage Therap ( (LCTX) ) has issued an update.
On November 20, 2025, Lineage Cell Therapeutics achieved a significant development milestone under its collaboration with Genentech and Roche for the OpRegen cell therapy program, triggering a $5 million payment. A portion of this payment will be distributed to the Israel Innovation Authority and Hadasit Medical Research and Development Ltd., reflecting the collaborative nature of the project and compliance with Israeli law.
The most recent analyst rating on (LCTX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.
Spark’s Take on LCTX Stock
According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.
Lineage Therap’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and substantial operational losses. While technical analysis shows positive momentum, and strategic partnerships offer long-term potential, the current financial challenges and negative valuation metrics weigh heavily on the stock’s attractiveness.
To see Spark’s full report on LCTX stock, click here.
More about Lineage Therap
Lineage Cell Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of cell therapy programs. Its primary product, OpRegen, is being developed for the treatment of ocular disorders, including geographic atrophy secondary to age-related macular degeneration.
Average Trading Volume: 1,906,726
Technical Sentiment Signal: Buy
Current Market Cap: $400.8M
For detailed information about LCTX stock, go to TipRanks’ Stock Analysis page.